University of Leicester
le.ac.ukTotal trials
165
Active
34
Phase 3
8
Total enrollment
16,242,953
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Low calorie meal replacement plan | — | — | — | — | — | 1 | |
| Sparsentan | — | — | — | — | — | 1 |
Next readouts
- 2025-03-31
- 2026-05-31
Top conditions
- Diabetes Mellitus, Type 213
- Cardiovascular Diseases9
- Type 2 Diabetes7
- Coronary Artery Disease7
- Asthma7
- Heart Failure6
- Diabetes5
- Heart Failure With Preserved Ejection Fraction5
Frequently asked questions about University of Leicester
- How many clinical trials does University of Leicester have on ClinicalTrials.gov?
- University of Leicester is listed as the lead sponsor on 165 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Leicester's trials are in Phase 3?
- 8 of University of Leicester's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Leicester focus on?
- University of Leicester's most-studied conditions on ClinicalTrials.gov are Diabetes Mellitus, Type 2, Cardiovascular Diseases, Type 2 Diabetes, Coronary Artery Disease, Asthma.
- When are University of Leicester's next clinical trial readouts?
- University of Leicester has 2 upcoming primary-completion readouts tracked here; the soonest is “A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy”, expected around 2025-03-31.